Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R348 in Chronic Ocular GVHD
NCT02040623Phase 2Completed
- Sponsor
- Rigel Pharmaceuticals, Inc.
- Start
- Mar 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of R348 in chronic ocular graft-versus-host disease (oGVHD), sponsored by Rigel Pharmaceuticals, Inc.. Started Mar 2014; status: completed.
02
Drugs
R348
03
Conditions
chronic ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT02040623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040623.